Victoria K. Woodcock

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Journal: Nature medicine
Published: January 17, 2026

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Journal: Nature medicine
Published: December 23, 2024

Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Journal: Nature communications
Published: April 24, 2024

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.

Journal: BJUI compass
Published: November 30, 2022

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Journal: Nature medicine
Published: April 06, 2022

Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Journal: Nature communications
Published: November 02, 2021

Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis.

Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: July 31, 2020

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 02, 2020

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Journal: Nature medicine
Published: October 29, 2019

Variability in body temperature in healthy adults and in patients receiving chemotherapy: prospective observational cohort study.

Variability in body temperature in healthy adults and in patients receiving chemotherapy: prospective observational cohort study.

Journal: Journal of medical engineering & technology
Published: October 04, 2019

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 17, 2018

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Journal: British journal of cancer
Published: July 31, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026